Finch Therapeutics Group Stock Forecast, Price & News

-0.10 (-0.58 %)
(As of 04/13/2021 12:00 AM ET)
Today's Range
Now: $17.00
50-Day Range N/A
52-Week Range
Now: $17.00
Volume118,741 shs
Average Volume257,346 shs
Market Capitalization$801.47 million
P/E RatioN/A
Dividend YieldN/A
Finch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company, engages in developing a novel class of orally administered biological drugs in the United States. Its lead candidate is CP101, an orally administered microbiome capsule that has completed Phase II clinical trial for the treatment of patients with recurrent Clostridioides difficile infection. The company is also developing CP101 for the chronic hepatitis B; FIN-211, an orally administered enriched consortia product candidate for the treatment of autism spectrum disorder; and FIN-524 and FIN-525, which are orally administered targeted consortia product candidates for the treatment of ulcerative colitis and crohn's disease. Finch Therapeutics Group, Inc. is based in Somerville, Massachusetts.

Industry, Sector and Symbol

Industry Biotechnology
Current SymbolNASDAQ:FNCH
Year FoundedN/A



Sales & Book Value

Annual SalesN/A



Market Cap$801.47 million
Next Earnings DateN/A
OptionableNot Optionable


Overall MarketRank

1.33 out of 5 stars

Medical Sector

757th out of 2,019 stocks

Biotechnology Industry

34th out of 145 stocks

Analyst Opinion: 0.0Community Rank: 5.0Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.0 5 -4 -3 -2 -1 -
-0.10 (-0.58 %)
(As of 04/13/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive FNCH News and Ratings via Email

Sign-up to receive the latest news and ratings for FNCH and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Finch Therapeutics Group (NASDAQ:FNCH) Frequently Asked Questions

What stocks does MarketBeat like better than Finch Therapeutics Group?

Wall Street analysts have given Finch Therapeutics Group a "N/A" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Finch Therapeutics Group wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Who are Finch Therapeutics Group's key executives?

Finch Therapeutics Group's management team includes the following people:
  • Mr. Mark Burnham Smith, CEO, Pres & Director
  • Mr. Gregory D. Perry, CFO & Treasurer (Age 61)
  • Ms. Kristine Callahan CPA, Sr. Director of Accounting
  • Ms. Sonia Timberlake, Sr. VP of Research
  • Mr. Andrew Noh, Chief Admin. Officer & Sec.
  • Mr. Joseph D. Vittiglio J.D., Esq., Gen. Counsel (Age 49)
  • Mr. James S. Sigler, Exec. VP of CMC (Age 60)
  • Mr. Zain Kassam, Chief Medical Officer
  • Mr. Kris Piper M.S., Sr. VP of Regulatory & Quality Assurance
  • Dr. Michelle L. Rose, Chief Regulatory Officer

Who are some of Finch Therapeutics Group's key competitors?

When did Finch Therapeutics Group IPO?

(FNCH) raised $101 million in an initial public offering (IPO) on Friday, March 19th 2021. The company issued 6,300,000 shares at a price of $15.00-$17.00 per share. BofA Securities, Jefferies and Evercore ISI acted as the underwriters for the IPO.

What is Finch Therapeutics Group's stock symbol?

Finch Therapeutics Group trades on the NASDAQ under the ticker symbol "FNCH."

When does the company's quiet period expire?

Finch Therapeutics Group's quiet period expires on Wednesday, April 28th. Finch Therapeutics Group had issued 7,500,000 shares in its IPO on March 19th. The total size of the offering was $127,500,000 based on an initial share price of $17.00. During the company's quiet period, insiders and underwriters involved in the IPO are restricted from issuing any research reports or earnings estimates for the company because of SEC regulations. Following the expiration of the company's quiet period, the brokerages that served as underwriters will likely initiate research coverage on the company.

How do I buy shares of Finch Therapeutics Group?

Shares of FNCH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Finch Therapeutics Group's stock price today?

One share of FNCH stock can currently be purchased for approximately $17.00.

How much money does Finch Therapeutics Group make?

Finch Therapeutics Group has a market capitalization of $801.47 million.

How many employees does Finch Therapeutics Group have?

Finch Therapeutics Group employs 131 workers across the globe.

What is Finch Therapeutics Group's official website?

The official website for Finch Therapeutics Group is

How can I contact Finch Therapeutics Group?

The company can be reached via phone at 617-229-6499.

This page was last updated on 4/13/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.